81 research outputs found
Ariel stellar characterisation: I -- homogeneous stellar parameters of 187 FGK planet host stars Description and validation of the method
In 2020 the European Space Agency selected Ariel as the next mission to join
the space fleet of observatories to study planets outside our Solar System.
Ariel will be devoted to the characterisation of a thousand planetary
atmospheres, for understanding what exoplanets are made of, how they formed and
how they evolve. To achieve the last two goals all planets need to be studied
within the context of their own host stars, which in turn have to be analysed
with the same technique, in a uniform way. We present the spectro-photometric
method we have developed to infer the atmospheric parameters of the known host
stars in the Tier 1 of the Ariel Reference Sample. Our method is based on an
iterative approach, which combines spectral analysis, the determination of the
surface gravity from {\em Gaia} data, and the determination of stellar masses
from isochrone fitting. We validated our approach with the analysis of a
control sample, composed by members of three open clusters with well-known ages
and metallicities. We measured effective temperature, Teff, surface gravity,
logg, and the metallicity, [Fe/H], of 187 F-G-K stars within the Ariel
Reference Sample. We presented the general properties of the sample, including
their kinematics which allows us to separate them between thin and thick disc
populations. A homogeneous determination of the parameters of the host stars is
fundamental in the study of the stars themselves and their planetary systems.
Our analysis systematically improves agreement with theoretical models and
decreases uncertainties in the mass estimate (from 0.21+/-0.30 to 0.10+/-0.02
M_sun), providing useful data for the Ariel consortium and the astronomical
community at large.Comment: Accepted for publication in A&A, 13 pages, 14 figures, Tables A1 and
A2 in the Appendix will be available at CDS and can be requested by email to:
[email protected]
Ictiobot-40 a low cost AUV platform for acoustic imaging surveying
Autonomous Underwater Vehicles (AUVs) are suitable platforms for a wide type of applications in the oceanic environment. These applications are developed in various fields such as scientific surveying, off-shore industry and defense. The employment of AUVs requires less human support and reduces operation costs. Due to the changing marine environment these vehicles must deal with uncertain and hostile conditions to perform its tasks. In the marine robotics matter, the INTELYMEC group has developed in 2012 an AUV prototype called Ictiobot, a low cost experimental platform for multipurpose missions. In this paper an upgrade of the original prototype is presented, the Ictiobot-40, conceived to perform acoustic imaging surveying missions of up to two hours and maximum depths of 40 meters. The new software and hardware architectures and mechanical structure improvements, are detailed. In addition to these technical details, initial experimental results of the AUV performance in quiet waters will be discussed. Also, the new approaches for systems under development are presented.Trabajo presentado en OCEANS 2019 (Marsella, 17 al 20 de junio de 2019
Ariel stellar characterisation. I. Homogeneous stellar parameters of 187 FGK planet host stars: Description and validation of the method
Context. In 2020 the European Space Agency selected Ariel as the next mission to join the space fleet of observatories to study planets outside our Solar System. Ariel will be devoted to the characterisation of 1000 planetary atmospheres in order to understand what exoplanets are made of, how they form, and how they evolve. To achieve the last two goals all planets need to be studied within the context of their own host stars, which in turn must be analysed with the same technique, in a uniform way. Aims: We present the spectro-photometric method we developed to infer the atmospheric parameters of the known host stars in the Tier 1 of the Ariel Reference Sample. Methods: Our method is based on an iterative approach that combines spectral analysis, the determination of the surface gravity from Gaia data, and the determination of stellar masses from isochrone fitting. We validated our approach with the analysis of a control sample, composed of members of three open clusters with well-known ages and metallicities. Results: We measured effective temperature Teff, surface gravity log g, and the metallicity [Fe/H] of 187 F-G-K stars within the Ariel Reference Sample. We presented the general properties of the sample, including their kinematics, which allows us to classify them into thin- and thick-disc populations. Conclusions: A homogeneous determination of the parameters of the host stars is fundamental in the study of the stars themselves and their planetary systems. Our analysis systematically improves agreement with theoretical models and decreases uncertainties in the mass estimate (from 0.21 ± 0.30 to 0.10 ± 0.02 M⊙), providing useful data for the Ariel consortium and the astronomical community at large. Tables A.1 and A.2 are only available at the CDS via anonymous ftp to cdsarc.u-strasbg.fr (ftp://130.79.128.5) or via http://cdsarc.u-strasbg.fr/viz-bin/cat/J/A+A/663/A161</A
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
SDSS-III: Massive Spectroscopic Surveys of the Distant Universe, the Milky Way Galaxy, and Extra-Solar Planetary Systems
Building on the legacy of the Sloan Digital Sky Survey (SDSS-I and II),
SDSS-III is a program of four spectroscopic surveys on three scientific themes:
dark energy and cosmological parameters, the history and structure of the Milky
Way, and the population of giant planets around other stars. In keeping with
SDSS tradition, SDSS-III will provide regular public releases of all its data,
beginning with SDSS DR8 (which occurred in Jan 2011). This paper presents an
overview of the four SDSS-III surveys. BOSS will measure redshifts of 1.5
million massive galaxies and Lya forest spectra of 150,000 quasars, using the
BAO feature of large scale structure to obtain percent-level determinations of
the distance scale and Hubble expansion rate at z<0.7 and at z~2.5. SEGUE-2,
which is now completed, measured medium-resolution (R=1800) optical spectra of
118,000 stars in a variety of target categories, probing chemical evolution,
stellar kinematics and substructure, and the mass profile of the dark matter
halo from the solar neighborhood to distances of 100 kpc. APOGEE will obtain
high-resolution (R~30,000), high signal-to-noise (S/N>100 per resolution
element), H-band (1.51-1.70 micron) spectra of 10^5 evolved, late-type stars,
measuring separate abundances for ~15 elements per star and creating the first
high-precision spectroscopic survey of all Galactic stellar populations (bulge,
bar, disks, halo) with a uniform set of stellar tracers and spectral
diagnostics. MARVELS will monitor radial velocities of more than 8000 FGK stars
with the sensitivity and cadence (10-40 m/s, ~24 visits per star) needed to
detect giant planets with periods up to two years, providing an unprecedented
data set for understanding the formation and dynamical evolution of giant
planet systems. (Abridged)Comment: Revised to version published in The Astronomical Journa
Minimal Length Scale Scenarios for Quantum Gravity
We review the question of whether the fundamental laws of nature limit our
ability to probe arbitrarily short distances. First, we examine what insights
can be gained from thought experiments for probes of shortest distances, and
summarize what can be learned from different approaches to a theory of quantum
gravity. Then we discuss some models that have been developed to implement a
minimal length scale in quantum mechanics and quantum field theory. These
models have entered the literature as the generalized uncertainty principle or
the modified dispersion relation, and have allowed the study of the effects of
a minimal length scale in quantum mechanics, quantum electrodynamics,
thermodynamics, black-hole physics and cosmology. Finally, we touch upon the
question of ways to circumvent the manifestation of a minimal length scale in
short-distance physics.Comment: Published version available at
http://www.livingreviews.org/lrr-2013-
The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
C−H Bond Activation Processes in Cationic and Neutral Titanium Benzyl Compounds with Cyclopentadienyl−Arene Ligands
Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study
Summary
Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally.
Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies
have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of
the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income
countries globally, and identified factors associated with mortality.
Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to
hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis,
exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a
minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical
status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary
intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause,
in-hospital mortality for all conditions combined and each condition individually, stratified by country income status.
We did a complete case analysis.
Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital
diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal
malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome
countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male.
Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3).
Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income
countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups).
Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome
countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries;
p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients
combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11],
p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20
[1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention
(ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety
checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed
(ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of
parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65
[0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality.
Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome,
middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will
be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger
than 5 years by 2030
- …